Skip to main content

Outage notice:

Due to the global information outage that occurred Friday, Quest is taking swift action to respond, recover and restore our operations. Our Patient Services are operating with reduced capacity so you may experience longer wait and service times. Our Customer Contact teams are currently unavailable. We appreciate your patience as we work toward returning to normal operations. 

Hide

Bleeding & thrombosis

Laboratory blood testing, together with a patient exam and medical history, is vital to correctly diagnosing bleeding and/or thrombotic disorders. Quest Diagnostics has a large, highly advanced test menu for these blood conditions.

Tests for bleeding disorders and thrombosis serve many functions, most notably detecting hemostasis defects and thrombosis risk, monitoring anticoagulant therapy, evaluating thrombotic conditions, and investigating the cause of abnormal PT and aPTT test results. Quest testing can be enhanced with consultative reports, interpretations, FAQs, and expert insight.

COVID-19 and coagulopathy

There is a growing body of evidence of a high prevalence of blood clots, strokes, heart attacks, and organ failures among patients infected with SARS-CoV-2 (COVID-19).1 Consider monitoring platelet count, PT/aPTT, D-Dimer, and fibrinogen. Continued monitoring of patients postdischarge is suggested for patients on extended prophylaxis.2

Watch video

Testing portfolio

  • Bleeding profiles and screening tests
  • von Willebrand disease
  • Factor assays and inhibitors
  • Anticoagulant therapy
  • HIT, TTP, and platelet studies
  • Fibrinolysis and markers of thrombin generation
  • Thrombotic risk markers and profiles–inherited
  • Antiphospholipid antibody and lupus anticoagulant
  • Women’s health
  • D-Dimer: D-Dimer is one of the measurable by-products of activation of the fibrinolytic system. Quantitation of D-Dimer assesses fibrinolytic activation and intravascular thrombosis. D-Dimer is of particular value in excluding the diagnosis of venous thromboembolism among patients at high risk.

The power of Quest

References

  1. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5

  2. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950-2973. doi:10.1016/j.jacc.2020.04.031


This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.